New Describe a product, get the CN code. Also as API and MCP for AI agents. Try it free
Jump to content

Tariff number 3004390000 80 - Other

Import trade restrictions for 3004390000 80

Duties for more codes with a free account

You have looked at the duties of 10 codes today. Sign up free to see duties, measures and history for every code.

Free account Many codes at once? Use the API

Preferential rules of origin for 3004390000

What the goods must meet to count as originating in a partner country and get the preferential duty, per agreement.

  • EU-Algeria Association Agreement · Algeria

    EU-Egypt Association Agreement · Egypt

    EU-Morocco Association Agreement · Morocco

    Medicaments (excluding goods of heading 3002, 3005 or 3006):

    – Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

    – Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • Generalised Scheme of Preferences (GSP, GSP+, EBA) · Armenia, India, Kenya, Pakistan, Samoa, Solomon Islands, Syria, Vietnam

    EU-Singapore FTA · Singapore

    Pharmaceutical products / or: Manufacture from materials of any heading

  • Autonomous Trade Preferences (Western Balkans) · Kosovo

    Medicaments (excluding goods of heading 3002, 3005 or 3006):

    - Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

    - Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EU-Canada CETA · Canada

    A change from within any one of these subheadings or any other subheading.

  • EU-Chile Association Agreement · Chile

    Medicaments (excluding goods of heading 3002, 3005 or 3006): — Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 or 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 or 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EU-Colombia/Peru/Ecuador Trade Agreement · Colombia, Ecuador, Peru

    Medicaments (excluding products of heading 3002, 3005 or 3006):

    Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product

    Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 per cent of the ex-works price of the product

  • EPA CARIFORUM

    Medicaments (excluding goods of heading No 3002, 3005 or 3006): – Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product – Other / or: Manufacture in which: – all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product; – the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EPA Eastern and Southern Africa

    – Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex works price of the product

  • EU Market Access Regulation (EPA) · Cameroon, Côte d’Ivoire, Ghana, Kenya

    Medicaments (excluding goods of heading No 3002, 3005 or 3006):

    – Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used is classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product

    – Other / or: Manufacture in which: all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product; the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EPA Pacific · Fiji, Papua New Guinea, Samoa, Solomon Islands

    Medicaments (excluding goods of heading No 3002, 3005 or 3006): – Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex works price of the product

  • EU-Israel Association Agreement · Israel

    Medicaments (excluding goods of heading Nos 3002, 3005 and 3006) / or: Manufacture in which: all the materials used are classified within a heading other than that of the product. However, materials of heading Nos 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product, and the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EU-Jordan Association Agreement · Jordan

    Medicaments (excluding goods of heading 3002, 3005 or 3006): - Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EU-Japan EPA · Japan

    CTSH; A chemical reaction, purification, mixing and blending, production of standard materials, a change in particle size, isomer separation or biotechnological processing is undergone; MaxNOM 50 % (EXW); or RVC 55 % (FOB).

  • EU-Korea FTA · South Korea

    Pharmaceutical products; except for: / or: Manufacture from materials of any heading, except that of the product. However, materials of the same heading as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  • EU-Central America Association Agreement

    Medicaments (excluding goods of heading 3002, 3005 or 3006): / or: Manufacture from materials of any heading, except that of the product and heading 3003

  • EU-Lebanon Association Agreement · Lebanon

    Medicaments (excluding goods of heading 3002, 3005 or 3006):

    – Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

    – Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EU-Mexico Global Agreement · Mexico

    Medicaments (excluding goods of heading No 3002, 3005 or 3006): — Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product — Other / or: Manufacture in which: all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product, the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EU-Palestine Interim Association Agreement · Palestine

    Medicaments (excluding goods of heading No 3002, 3005 or 3006): - Obtained from amikacin of heading No 2941 - Other / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex works price of the product Manufacture in which: all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20% of the ex-works price of the product; the value of all the materials used does not exceed 50% of the ex-works price of the product

  • EU-Tunisia Association Agreement · Tunisia

    Medicaments (excluding goods of heading 3002, 3005 or 3006): Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

  • EU-Viet Nam FTA · Vietnam

    Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or in forms of packing for retail sale. / or: Manufacture from materials of any heading, except that of the product; or manufacture in which the value of all the materials used does not exceed 70 % of the ex-works price of the product.

Source: European Commission, Access2Markets (CC BY 4.0, shortened). The text of the agreement prevails. Access2Markets

Legal and explanatory notes for 3004390000

3004 CN Explanatory Notes: Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale

See additional note 1 to this chapter. Unlike the previous heading, this heading covers ‘unmixed products’. For the interpretation of the term ‘unmixed products’, see note 3(a) to this chapter and the HS Explanatory Note to heading 3004, fourth and fifth paragraphs. The terms ‘in measured doses (including those in the form of transdermal administration systems)’ and ‘forms or packings for retail sale for therapeutic or prophylactic uses’ are defined in the HS Explanatory Note to heading 3004, first and second paragraphs. Medicaments put up in packings for long-term administration or for hospitals and similar establishments are included here. In this case, a larger number of units of the product is contained and the intended long-term administration or hospital use is generally indicated on the packing. The fact that medicaments containing, for example, antibiotics, hormones or lyophilised products, and put up in ampoules or bottles must still have added to them pyrogen-free water or another diluent before being administered, does not exclude them from this heading. The heading includes, inter alia, preparations containing a sufficient quantity of active substances per daily dose (e.g. hormones or co-factors) to provide therapeutic or prophylactic effects against a specific disease or ailment. The daily dose is recommended on the label, packaging or on the accompanying user directions of such products. The index of Anatomical Therapeutic Chemicals (WHO ATC-DDD index) (https://www.whocc.no/atc_ddd_index/), developed by the World Health Organisation (WHO), indicates the Defined Daily Dose (DDD) providing therapeutic or prophylactic effect when applied in quantities equal to or exceeding the amounts listed in that index. The following table shows the DDD for the substances listed: Name of the active substance | Defined Daily Dose | Unit | Administration route α-lipoic acid or thioctic acid | 0,6 | g | oral 0,6 | g | parenteral Glucosamine sulfate | 1,5 | g | oral Levocarnitine | 2 | g | oral 2 | g | parenteral Lovastatin | 45 | mg | oral Melatonin | 2 | mg | oral N-acetylcysteine | 0,5 | g | oral Yohimbine | 15 | mg | oral

Notes to chapter 30

Notes 1. This chapter does not cover: (a) foods or beverages (such as dietetic, diabetic or fortified foods, food supplements, tonic beverages and mineral waters), other than nutritional preparations for intravenous administration (Section IV); (b) products, such as tablets, chewing gum or patches (transdermal systems), containing nicotine and intended to assist tobacco use cessation (heading 2404); (c) plasters specially calcined or finely ground for use in dentistry (heading 2520); (d) aqueous distillates or aqueous solutions of essential oils, suitable for medicinal uses (heading 3301); (e) preparations of headings 3303 to 3307, even if they have therapeutic or prophylactic properties; (f) soap or other products of heading 3401 containing added medicaments; (g) preparations with a basis of plaster for use in dentistry (heading 3407); (h) blood albumin not prepared for therapeutic or prophylactic uses (heading 3502); or (ij) diagnostic reagents of heading 3822. 2. For the purposes of heading 3002, the expression ‘immunological products’ applies to peptides and proteins (other than goods of heading 2937) which are directly involved in the regulation of immunological processes, such as monoclonal antibodies (MAB), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFN), chemokines and certain tumour-necrosis factors (TNF), growth factors (GF), hematopoietins and colony-stimulating factors (CSF). 3. For the purposes of headings 3003 and 3004 and of note 4(d) to this chapter, the following are to be treated: (a) as unmixed products: (1) unmixed products dissolved in water; (2) all goods of Chapter 28 or 29; and (3) simple vegetable extracts of heading 1302, merely standardised or dissolved in any solvent; (b) as products which have been mixed: (1) colloidal solutions and suspensions (other than colloidal sulphur); (2) vegetable extracts obtained by the treatment of mixtures of vegetable materials; and (3) salts and concentrates obtained by evaporating natural mineral waters. 4. Heading 3006 applies only to the following, which are to be classified in that heading and in no other heading of the nomenclature: (a) sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure; (b) sterile laminaria and sterile laminaria tents; (c) sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable; (d) opacifying preparations for X-ray examinations and diagnostic reagents designed to be administered to the patient, being unmixed products put up in measured doses or products consisting of two or more ingredients which have been mixed together for such uses; (e) placebos and blinded (or double-blinded) clinical trial kits for use in recognised clinical trials, put up in measured doses, even if they might contain active medicaments; (f) dental cements and other dental fillings; bone reconstruction cements; (g) first-aid boxes and kits; (h) chemical contraceptive preparations based on hormones, on other products of heading 2937 or on spermicides; (ij) gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments; (k) waste pharmaceuticals, that is, pharmaceutical products which are unfit for their original intended purpose due to, for example, expiry of shelf life; and (l) appliances identifiable for ostomy use, that is, colostomy, ileostomy and urostomy pouches cut to shape and their adhesive wafers or faceplates. Subheading notes 1. For the purposes of subheadings 3002 13 and 3002 14, the following are to be treated: (a) as unmixed products, pure products, whether or not containing impurities; (b) as products which have been mixed: (1) the products mentioned in (a) above dissolved in water or in other solvents; (2) the products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and (3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive. 2. Subheadings 3003 60 and 3004 60 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients : amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN). Additional note 1. Heading 3004 includes herbal medicinal preparations and preparations based on the following active substances: vitamins, minerals, essential amino-acids or fatty acids, in packings for retail sale. These preparations are classified in heading 3004 if they bear on the label, packaging or on the accompanying user directions the following statements of: (a) the specific diseases, ailments or their symptoms for which the product is to be used; (b) the concentration of active substance or substances contained therein; (c) dosage; and (d) mode of application. This heading includes homeopathic medicinal preparations when they meet the conditions of (a), (c) and (d) mentioned above. In the case of preparations based on vitamins, minerals, essential amino-acids or fatty acids, the level of one of these substances per recommended daily dose indicated on the label must be significantly higher than the recommended daily allowance to maintain general health or well-being.

Other explanatory notes for the chapter

Additional note 1 1. Herbal medicinal preparations are preparations based on one or more active substances, produced by subjecting a plant or parts thereof to a process such as drying, crushing, extraction or purification. Active substance means a chemically defined substance, a chemically defined group of substances (for example, alkaloids, polyphenols, anthocyanins) or a plant extract. These active substances must have medicinal properties for the prevention or the treatment of specific diseases, ailments or their symptoms. 2. Homeopathic medicinal preparations are prepared from products, substances or compositions called homeopathic stocks (mother tinctures). The degree of dilution must be indicated (for example, D6). 3. Vitamins or mineral preparations are preparations based on vitamins of heading 2936, on minerals including trace elements and mixtures thereof. They are used to treat or prevent specific diseases, ailments or their symptoms. Such preparations contain a much higher amount of vitamins or minerals, generally at least three times higher than the recommended daily allowance (RDA). As regards the recommended daily allowance (RDA) for certain vitamins and minerals, see, for example, the table in the Annex XIII to Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers (OJ L 304, 22.11.2011, p. 58) reproduced below: Vitamins and minerals | RDA Vitamin A | 800 μg Vitamin D | 5 μg Vitamin E | 12 mg Vitamin K | 75 μg Vitamin C | 80 mg Thiamin 1,1 mg Riboflavin | 1,4 mg Niacin 16 mg Vitamin B6 | 1,4 mg Folic acid | 200 μg Vitamin B12 | 2,5 μg Biotin 50 μg Pantothenic acid | 6 mg Potassium | 2 000 mg Chloride 800 mg Calcium 800 mg Phosphorus | 700 mg Magnesium | 375 mg Iron 14 mg Zinc 10 mg Copper 1 mg Manganese | 2 mg Fluoride 3,5 mg Selenium 55 μg Chromium 40 μg Molybdenum | 50 μg Iodine 150 μg 4. Recommended daily allowance (RDA) for adults with a weight of 70 kg, on essential amino acids, according to the joint WHO/FAO/UNU expert Consultation 2007: Essential Amino Acid | RDA (mg) Histidine | 700 Isoleucine | 1 400 Leucine 2 730 Lysine 2 100 Methionine + Cysteine | 1 050 Cysteine 287 Methionine | 728 Phenylalanine + Tyrosine | 1 750 Threonine | 1 050 Tryptophan | 280 Valine 1 820 Recommended daily allowance (RDA) for adults with a weight of 70 kg, on essential fatty acids, according to the joint WHO/FAO/UNU expert Consultation 2007. Types of essential fatty acids | Name of essential fatty acid | RDA (g) n-3 polyunsaturated fatty acids | linolenic acid (ALA) | 2 long-chain n-3 polyunsaturated fatty acids | EPA plus DHA | 0,25 n-6 polyunsaturated fatty acids | linoleic acid | 10

Sources: Combined Nomenclature 2026, Annex I to Regulation (EEC) No 2658/87 (CELEX 32025R1926), and the Explanatory Notes to the Combined Nomenclature (CELEX 02019XC0329(02)-20260213). The section and chapter notes are legally binding; the explanatory notes are guidance. EUR-Lex

EU trade in 2025 for 300439

Extra-EU imports
€6B
6,831 t
Extra-EU exports
€24.2B

Top origin countries by import value

  1. China €2.7B
  2. Switzerland €1.4B
  3. United States €690.4M
  4. United Kingdom €230.5M
  5. Canada €157.1M

CN8 codes below this code: 1. Source: Eurostat, Comext, CC BY 4.0, processed by hscode.info. Confidential trade is not allocated to codes.

HS 2028 change

This subheading changes on 1 January 2028.

HS 2022 subheading 300439 is split. New HS 2028 subheadings: 300433, 300439.

From the WCO HS 2022 to HS 2028 correlation tables, a guide only. The EU sets its own CN codes for 2028.

UK import duty for 300439

  • 0%

Third-country duties of all UK commodity codes under this HS subheading. Source: UK Department for Business and Trade, as of Nov 2, 2026. The UK tariff differs from the EU tariff.

Import VAT in the EU

  • Austria 20 %
  • Belgium 21 % maybe 6 %
  • Bulgaria 20 %
  • Croatia 25 % maybe 5 %
  • Cyprus 19 % maybe 5 %
  • Czechia 21 % maybe 12 %
  • Denmark 25 %
  • Estonia 24 % maybe 9 %
  • Finland 25.5 % maybe 13.5 %
  • France 20 % maybe 2.1 %, 10 %
  • Germany 19 %
  • Greece 24 % maybe 6 %, 13 %
  • Hungary 27 %
  • Ireland 23 %
  • Italy 22 % maybe 10 %
  • Latvia 21 % maybe 12 %
  • Lithuania 21 % maybe 5 %
  • Luxembourg 17 % maybe 3 %
  • Malta 18 %
  • Netherlands 21 % maybe 9 %
  • Poland 23 %
  • Portugal 23 % maybe 6 %
  • Romania 21 % maybe 11 %
  • Slovakia 23 % maybe 5 %
  • Slovenia 22 % maybe 9.5 %
  • Spain 21 %
  • Sweden 25 %

Standard rate per member state, on the customs value, the duty and transport to the destination. Reduced rates often depend on the use or the buyer and apply only where the country provides them for these goods. Source: European Commission, Taxes in Europe Database, as of Nov 2, 2026.

Rules of origin

Preferential rules of origin for subheading 300439 depend on the trade agreement. The Commission publishes them in Access2Markets.

Rules of origin on Access2Markets

Information

When importing or exporting "Other", it is crucial to have the correct HS code or TARIC code. The HS code 3004390000 80 serves as the standard code for this product, ensuring that the appropriate duties and taxes are applied when crossing international borders.

To ensure your business transactions run smoothly when importing or exporting "Other", consider the following points:

  1. Inform yourself about the specific import and export regulations in the countries involved. This includes possible restrictions, taxes, and duties applicable to "Other".
  2. Check if any additional licenses, permits, or certificates are required to import "Other" into the destination country or export it from the country of origin.
  3. Make sure your trading partners have valid identification numbers, such as EORI numbers (Economic Operators Registration and Identification) in the EU, to streamline trade and minimize delays.
  4. Ensure that all trade- and customs-related documents (such as commercial invoices, packing lists, certificates of origin, and insurance policies) are accurately completed and adhere to the respective national regulations.
  5. Keep an eye on the current exchange rates, as well as packaging, shipping, and insurance costs, to accurately calculate trade costs.

In summary, the HS code or TARIC code for "Other" is 3004390000 80. Make sure you accurately use this code in all your trade and customs documents to guarantee smooth and hassle-free transactions. With these tips, you'll be better prepared for the challenges of international trade and can successfully import and export "Other".

HS Code structure

30
Chapter
04
Heading
39
Subheading
00
CN Subheading
00
TARIC Subheading
80
Additional TARIC codes

1. Chapter

There are 21 different sections, which are divided into 96 chapters. Exceptional chapters include chapter 77, which is reserved for future use, chapters 98 and 99, which are limited at national level, and chapter 99, which is a specific code for temporary changes. In the example above, chapter 30 was selected for pharmaceutical products

2. Heading

The heading determines the specific category within a certain chapter. In the example above, the 04 refers to Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale.

3. Subheading

The last two digits of the international harmonized code are more specific and define subcategories of products. In the example above, the 39 refers to Other.

HS Code tree structure

3000000000 80

Chapter PHARMACEUTICAL PRODUCTS

3004000000 80

Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale

3004100000 80

- Containing penicillins or derivatives thereof, with a penicillanic acid structure, or streptomycins or their derivatives

3004200000 80

- Other, containing antibiotics

3004310000 10

- Other, containing hormones or other products of heading 2937

3004310000 80

- - Containing insulin

3004320000 80

- - Containing corticosteroid hormones, their derivatives or structural analogues

3004390000 80

- - Other

3004410000 10

- Other, containing alkaloids or derivatives thereof

3004410000 80

- - Containing ephedrine or its salts

3004420000 80

- - Containing pseudoephedrine (INN) or its salts

3004430000 80

- - Containing norephedrine or its salts

3004490000 80

- - Other

3004500000 80

- Other, containing vitamins or other products of heading 2936

3004600000 80

- Other, containing antimalarial active principles described in Subheading Note 2 to this Chapter

3004900000 80

- Other